Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial (CROSBI ID 323656)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Holmes, Frankie A. ; Moy, Beverly ; Delaloge, Suzette ; Chia, Stephen K.L. ; Ejlertsen, Bent ; Mansi, Janine ; Iwata, Hiroji ; Gnant, Michael ; Buyse, Marc ; Barrios, Carlos H. ; Silovski, Tajana ; Šeparović, Robert ; Bashford, Anna ; Zotano, Angel Guerrero ; Denduluri, Neelima ; Patt, Debra ; Gokmen, Erhan ; Gore, Ira ; Smith, John W. ; Loibl, Sibylle ; Masuda, Norikazu ; Tomašević, Zorica ; Petráková, Katarina ; DiPrimeo, Daniel ; Wong, Alvin ; Martin, Miguel ; Chan, Arlene
engleski
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
ExteNET showed that neratinib, an irreversible pan-HER tyrosine ki- nase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved inva- sive disease-free survival in women with early-stage HER2-positive breast cancer. We report the final analysis of overall survival in ExteNET.
Breast Neoplasms ; Chemotherapy ; Adjuvant ; Kaplan–Meier estimate ; Neratinib ; Receptor ErbB-2 ; Survival analysis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti
